Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Spyre Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Spyre Therapeutics's regulatory disclosures and financial reporting.
Spyre Therapeutics, Inc. reported a net loss of $69.0 million for the quarter ended March 31, 2026, wider than $44.8 million a year earlier, driven mainly by higher research and development spending of $60.4 million and increased general and administrative expenses of $15.2 million.
The company recorded a $30.0 million gain from a milestone on the prior sale of pegzilarginase rights to Immedica, while its contingent value right (CVR) liability rose to $56.9 million. Cash, cash equivalents and marketable securities totaled $741.5 million as of March 31, 2026, before an additional $435.3 million in net proceeds from an April 2026 equity offering.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a planned option exercise and share sale on Common Stock. On May 1, 2026, he sold 12,500 shares of Common Stock in an open-market transaction at $71.37 per share, pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
The same day, he exercised stock options to acquire 12,500 shares of Common Stock at an exercise price of $14.50 per share. Following these transactions, he directly holds 97,994 shares of Common Stock, which include 67,476 restricted stock units scheduled to vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. He also retains stock options representing a right to purchase 404,857 shares of Common Stock, vesting over several years.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan reported coordinated stock trades involving both option exercise and share sales. On May 1, 2026, Sloan exercised stock options to acquire 78,333 shares of common stock at an exercise price of $27.46 per share.
That same day, Sloan executed multiple open-market sales totaling 78,333 shares of common stock at weighted average prices reported around the low- to mid-$70s per share, with detailed price ranges from $69.21 to $74.96 disclosed in the footnotes. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025.
The option exercised covers a grant originally for 400,000 shares of common stock, with 321,667 option shares remaining outstanding after this exercise and an expiration date of October 1, 2034, subject to continued vesting based on employment.
Spyre Therapeutics, Inc. Chief Executive Officer Cameron Turtle reported selling 15,000 shares of common stock in multiple open-market transactions on May 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan.
The sales occurred at weighted-average prices, with transaction price ranges disclosed between $69.25 and $74.96 per share across several blocks. After these transactions, the filing shows that Turtle continues to hold Spyre common stock directly.
SYRE reports transactions in Common Stock under Rule 144. The excerpt lists an exercise of stock options resulting in 78,333 shares on 05/01/2026, and prior 10b5-1 sales of 7,958 shares on 04/01/2026 for $397,900. Broker: Morgan Stanley Smith Barney LLC.
Company reporting a Form 144 filing that lists 27,500 shares of Common Stock proposed for sale. The filing ties the sale to an exercise of stock options on 05/01/2026 with cash indicated as the method. The filing also discloses recent 10b5-1 sales: 7,500 shares sold on 04/01/2026 for $370,066.25 and 2,500 shares sold on 03/03/2026 for $101,620.50.
SPYRE THERAPEUTICS, INC. Schedule 13G: Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report beneficial ownership of 4,319,496 shares of Common Stock, representing 5.0% of the class. The filing states the outstanding share count as 85,664,811 shares as reported in a prospectus supplement filed April 16, 2026. Perceptive Life Sciences Master Fund directly holds the shares; Perceptive Advisors and Mr. Edelman disclose shared voting and dispositive power as investment manager and managing member, respectively.
Spyre Therapeutics' major shareholders have reaffirmed their stakes and agreed to a short-term lock-up. Fairmount Funds Management LLC and Fairmount Healthcare Fund II L.P. report beneficial ownership of 8,184,941 shares, or 9.09% of Spyre’s common stock, including common shares and Series A preferred stock on an as-converted basis, subject to a 9.99% beneficial ownership limitation. Individuals Peter Harwin and Tomas Kiselak each report beneficial ownership of 9,016,702 shares, or 9.99% of the class, combining direct holdings, options exercisable within 60 days, and Fund II’s preferred and common shares. The amendment notes that these ownership levels are unchanged from the prior amendment and is filed primarily to disclose that the reporting persons entered into a 60-day lock-up agreement in connection with the company’s underwritten public offering, during which they have agreed not to sell Spyre securities without underwriter consent.
Spyre Therapeutics, Inc. entered an underwriting agreement for a public offering of 6,500,000 shares of common stock at $62.00 per share, plus a 30‑day option for 975,000 additional shares that the underwriters fully exercised. The offering, made off an effective Form S-3 shelf, closed with gross proceeds of about $463.5 million before fees and expenses. Spyre plans to use the net proceeds to advance its inflammatory bowel disease and rheumatic disease programs, including preclinical work, clinical trials, manufacturing and Phase 3 readiness for its antibody programs, and for working capital and general corporate purposes.
Spyre Therapeutics, Inc. is offering 6,500,000 shares of its common stock at a public offering price of $62.00 per share, representing a total public offering price of $403,000,000. The company expects to receive approximately $378.8M in proceeds before expenses and has granted the underwriters a 30-day option to purchase up to 975,000 additional shares. The underwriters expect to deliver the shares on or about April 16, 2026. The prospectus supplement states the company had approximately $741M of cash, cash equivalents and marketable securities as of March 31, 2026, and that net proceeds will fund its IBD and rheumatic disease antibody programs, development activities, manufacturing and general corporate purposes.